Endocarditis surgery

Endocarditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Infective Endocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

Diagnosis and Follow-up

Medical Therapy

Intervention

Case Studies

Case #1

Endocarditis surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Endocarditis surgery

CDC onEndocarditis surgery

Endocarditis surgery in the news

Blogs on Endocarditis surgery

to Hospitals Treating Endocarditis surgery

Risk calculators and risk factors for Endocarditis surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Cafer Zorkun, M.D., Ph.D. [2] Maliha Shakil, M.D. [3]

## Overview[edit | edit source]

Early valve surgery should be scheduled when there is heart failure due to the valve dysfunction, left-sided infective endocarditis due to Staphylococcus aureus, fungal or highly resistant organisms, or a heart block, annular or aortic abscess or destructive lesions. Other indications include persistent bacteremia or fever 5 to 7 following the initiation of the antibiotics, relapse of the infection despite a complete course of antibiotics in prosthetic valve endocarditis when no portal of infection can be identified, recurrent emboli and persistent vegetations despite antibiotic therapy, and mobile vegetations with a length more than 10 mm in native valve endocarditis. Surgical removal of the valve is necessary for patients who fail to clear micro-organisms from their blood in response to antibiotic therapy, or in patients who develop cardiac failure resulting from destruction of a valve by infection. A removed valve is usually replaced with an artificial valve which may either be mechanical (metallic) or obtained from an animal such as a pig; the latter are termed bioprosthetic valves. Surgical treatment of endocarditis involves excision of all infected valve tissue, drainage and debridement of abscess cavities, repair or replacement of damaged valves, and repair of any associated pathology such as fistulas or septal defects.

## Surgery[edit | edit source]

### Indications[edit | edit source]

Indications for surgical debridement of vegetations and infected perivalvular tissue, with valve replacement or repair as needed, are listed below:[1]

1. Moderate to severe congestive heart failure due to valve dysfunction
2. Unstable valve prosthesis
3. Uncontrolled infection for > 1–3 week despite maximal antimicrobial therapy
4. Persistent bacteremia
5. Fungal endocarditis
6. Relapse after optimal therapy in a prosthetic valve
7. Vegetation in Situ
8. Prosthetic valve endocarditis with a perivalvular invasion
9. Endocarditis caused by Pseudomonas aeruginosa or other gram-negative bacilli that have not responded after 7–10 days of maximal antimicrobial therapy
10. Perivalvular extension of infection and abscess formation
11. Staphylococcal infection of prosthesis
12. Persistent fever (culture negative)
13. Large vegetation (>10 mm is associated with an increased risk of embolism)
14. Relapse after optimal therapy in a native valve
15. Vegetations that obstruct the valve orifice
16. Onset of AV block

## Principles of Surgical Treatment of Endocarditis[edit | edit source]

Surgical treatment of endocarditis includes:[1]

* Excision of all infected valve tissue
* Drainage and debridement of abscess cavities
* Repair or replacement of damaged valves
* Repair of any associated pathology such as septal defect, fistulas

## Aortic Valve - Surgical Options[edit | edit source]

If the infection is limited to the leaflets, then the aortic valve should be replaced. If the infection extends to the annulus or beyond, then the infected tissues should be debrided. Any abscesses should be drained and the aortic root should be replaced.

## Atrioventricular Valve - Surgical Options[edit | edit source]

If the infection is limited to the leaflets, then the vegetations should be excised, perforations should be repaired, and a reduction annuloplasty should be performed. If the infection extends to the annulus or beyond, then a valve replacement should be performed, and abscesses should be debrided and obliterated. In some cases the tricuspid valve may be excised.

## Surgical Outcomes[edit | edit source]

Operative mortality is 15 - 20%. The development of an infection of a prosthetic valve during operation for native valve endocarditis is 4%, it is higher (12 - 16%) if active endocarditis is present at the time of the surgery. Late survival at 5 years for native valve endocarditis is 70 - 80% and for prosthetic valve endocarditis is 50 - 80%.[1]

## References[edit | edit source]

1. ↑ 1.0 1.1 1.2 Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.CS1 maint: Multiple names: authors list (link)

Template:WH Template:WS